Acorda Therapeutics, Inc. (NASDAQ:ACOR) Files An 8-K Other Events
Item 8.01Other Events
On March 29, 2017, Acorda Therapeutics, Inc. (the Company) issued
a press release announcing results from two ongoing, long-term
safety studies of CVT-301 in people with Parkinsons that showed
no differences in pulmonary function between the group receiving
CVT-301 and an observational control group. These results are
consistent with previously reported data from Phase 2b and Phase
3 clinical trials. The Company also announced results from
separate clinical studies that assessed the safety profile of
CVT-301 in people with asthma, smokers and early morning OFF.
CVT-301 is an investigational, inhalable formulation of levodopa
(L-dopa). It is being studied as a treatment for symptoms of OFF
periods in people with Parkinsons taking an oral carbidopa /
levodopa regimen. OFF periods are characterized by the
re-emergence of Parkinsons disease symptoms. The Company plans to
file a New Drug Application (NDA) in the United States by the end
of the second quarter of 2017 and, pending additional data
analyses, plans to file a Marketing Authorization Application
(MAA) in Europe by the end of 2017. A copy of the press release
is attached as Exhibit 99.1 to this Current Report on Form 8-K,
and incorporated by reference into this Item 8.01.
Item 9.01Financial Statements and Exhibits
(d) Exhibits
|
Exhibit No. |
Description |
|
99.1 |
Press Release dated March 29, 2017 |
About Acorda Therapeutics, Inc. (NASDAQ:ACOR)
Acorda Therapeutics, Inc. is a biopharmaceutical company. The Company is engaged in the identification, development and commercialization of therapies that restore function and recovers the lives of people with neurological disorders. Its commercial products include Ampyra, Fampyra, Zanaflex Capsules and a generic version of the capsules, Zanaflex tablets and Qutenza. Its research and development programs include CVT-301, Dalfampridine, Plumiaz, Neuregulin Program, Remyelinating Antibodies Program, CVT-427 and Chondroitinase Program. Its Ampyra is an oral drug for the treatment to improve walking in patients with multiple sclerosis. Zanaflex Capsules and tablets are used as short-acting drugs for the management of spasticity. Qutenza is a dermal patch for the management of neuropathic pain associated with post-herpetic neuralgia. Its pipeline of neurological therapies addresses a range of disorders, including Parkinson’s disease, chronic post-stroke walking deficits and migraine. Acorda Therapeutics, Inc. (NASDAQ:ACOR) Recent Trading Information
Acorda Therapeutics, Inc. (NASDAQ:ACOR) closed its last trading session down -0.30 at 26.10 with 314,971 shares trading hands.
